Compare AX & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AX | LNTH |
|---|---|---|
| Founded | 1999 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.3B |
| IPO Year | 2004 | 2014 |
| Metric | AX | LNTH |
|---|---|---|
| Price | $94.25 | $81.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $103.14 | $87.00 |
| AVG Volume (30 Days) | 311.6K | ★ 581.3K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 4.17 | 3.41 |
| Revenue | $65,789,000.00 | ★ $343,374,000.00 |
| Revenue This Year | $24.76 | N/A |
| Revenue Next Year | $10.86 | $14.19 |
| P/E Ratio | ★ $23.76 | $24.33 |
| Revenue Growth | 1.78 | ★ 3.62 |
| 52 Week Low | $62.35 | $47.27 |
| 52 Week High | $101.92 | $108.86 |
| Indicator | AX | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 54.46 | 51.90 |
| Support Level | $90.96 | $72.35 |
| Resistance Level | $100.44 | $84.58 |
| Average True Range (ATR) | 2.72 | 2.15 |
| MACD | 0.13 | -0.18 |
| Stochastic Oscillator | 45.19 | 28.11 |
Axos Financial Inc is a bank holding company that operates through its bank subsidiary, BofI Federal Bank, a nationwide bank that provides financing for single and multifamily residential properties, small to medium-size businesses in certain sectors, and selected specialty finance receivables. Its operating segments are banking business segment and securities business segment. The bank distributed its products through a wide range of retail distribution channels, including only banking brands, affinity groups, and sales teams, among others. The majority of the bank's mortgage exposure is titled toward the state of California, particularly its southern region. Net interest income is a majority of the bank's revenue.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.